Actively Recruiting
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
Led by University of Pennsylvania · Updated on 2026-05-11
12
Participants Needed
1
Research Sites
882 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label, phase 1b study to evaluate different approaches for CART-EGFR-IL13Ra2 dosing and further characterize the safety, feasibility, preliminary efficacy, and pharmacokinetics of CART-EGFR-IL13Ra2 cells in patients with EGFR-amplified glioblastoma that has recurred following prior radiotherapy.
CONDITIONS
Official Title
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed, written informed consent
- Male or female age 63 18 years
- Glioblastoma, IDH-wildtype, recurrent after prior radiotherapy
- Tumor tissue positive for wild-type EGFR amplification
- Surgical tumor resection or tumor biopsy clinically indicated
- Adequate organ function including creatinine, liver enzymes, bilirubin, heart function, and pulmonary reserve
- Karnofsky Performance Status 63 60%
- Agreement to use acceptable birth control methods if of reproductive potential
You will not qualify if you...
- Active hepatitis B or hepatitis C infection
- Any other active, uncontrolled infection
- Class III/IV cardiovascular disability
- Tumors primarily in brain stem or spinal cord
- Severe active co-morbidity preventing study participation
- Receipt of bevacizumab within 3 months prior to eligibility confirmation
- Active autoimmune disease needing systemic immunosuppressive treatment 63 10 mg prednisone daily
- Autoimmune neurological diseases such as MS or Parkinson's
- Pregnancy or nursing (lactating)
- Allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, Dextran 40)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
A
Abramson Cancer Center Clinical Trials, MD, MSCE
CONTACT
U
University of Pennsylvania
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here